\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{3}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{4}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics vs Genomics}{4}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{4}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{4}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences}{4}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}Role of computational biology}{4}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Human Genomics - the Basis}{5}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Genetic Make-Up}{5}{subsection.1.2.1}%
\contentsline {subsubsection}{\numberline {1.2.1.1}Single nucleotide polymorphisms}{5}{subsubsection.1.2.1.1}%
\contentsline {subsubsection}{\numberline {1.2.1.2}Copy number variants}{5}{subsubsection.1.2.1.2}%
\contentsline {subsection}{\numberline {1.2.2}Inherited variants' relevance}{5}{subsection.1.2.2}%
\contentsline {paragraph}{\numberline {1.2.2.0.1}Penetrance}{5}{paragraph.1.2.2.0.1}%
\contentsline {paragraph}{\numberline {1.2.2.0.2}Allele frequency}{6}{paragraph.1.2.2.0.2}%
\contentsline {subsection}{\numberline {1.2.3}Differences in Genetic Make-Up, an example}{6}{subsection.1.2.3}%
\contentsline {subsection}{\numberline {1.2.4}Acquired DNA aberrations}{6}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Types of acquired DNA aberrations}{6}{subsubsection.1.2.4.1}%
\contentsline {paragraph}{\numberline {1.2.4.1.1}Translocation}{6}{paragraph.1.2.4.1.1}%
\contentsline {paragraph}{\numberline {1.2.4.1.2}Inversion}{6}{paragraph.1.2.4.1.2}%
\contentsline {paragraph}{\numberline {1.2.4.1.3}Copy number changes}{7}{paragraph.1.2.4.1.3}%
\contentsline {paragraph}{\numberline {1.2.4.1.4}Chromoplexy}{7}{paragraph.1.2.4.1.4}%
\contentsline {paragraph}{\numberline {1.2.4.1.5}Chromothripsis}{7}{paragraph.1.2.4.1.5}%
\contentsline {paragraph}{\numberline {1.2.4.1.6}Kataegis}{7}{paragraph.1.2.4.1.6}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{7}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Cariotyping}{7}{subsection.1.3.1}%
\contentsline {section}{\numberline {1.4}Sequence capture for cancer genomics}{7}{section.1.4}%
\contentsline {subsection}{\numberline {1.4.1}Single End (SE) and Paired End (PE) reads}{7}{subsection.1.4.1}%
\contentsline {part}{II\hspace {1em}Papers}{9}{part.2}%
\contentsline {chapter}{\numberline {2}Role of non-coding sequence variants in cancer}{10}{chapter.2}%
\contentsline {section}{\numberline {2.1}Abstract}{10}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Introduction}{10}{subsection.2.1.1}%
\contentsline {section}{\numberline {2.2}Genomic sequence variants}{10}{section.2.2}%
\contentsline {section}{\numberline {2.3}Non-coding element annotation}{11}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}Cis regulatory regions}{11}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Distal regulatory elements}{11}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}RNA-seq}{11}{subsection.2.3.3}%
\contentsline {subsection}{\numberline {2.3.4}Transcribed pseudogenes}{11}{subsection.2.3.4}%
\contentsline {subsection}{\numberline {2.3.5}Evolutionary conservation}{12}{subsection.2.3.5}%
\contentsline {section}{\numberline {2.4}Roles for somatic variants in cancer}{12}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Gain of TF-binding sites}{12}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}Fusion events due to genomic rearrangements}{12}{subsection.2.4.2}%
\contentsline {subsection}{\numberline {2.4.3}ncRNAs and their binding sites}{12}{subsection.2.4.3}%
\contentsline {subsection}{\numberline {2.4.4}Role of pseudogenes in modulating the expression of a parental gene}{13}{subsection.2.4.4}%
\contentsline {section}{\numberline {2.5}Roles for germline variants in cancer}{13}{section.2.5}%
\contentsline {subsection}{\numberline {2.5.1}Promoter mutations}{13}{subsection.2.5.1}%
\contentsline {subsection}{\numberline {2.5.2}SNPs in enhancers}{13}{subsection.2.5.2}%
\contentsline {subsection}{\numberline {2.5.3}Variants in introns}{13}{subsection.2.5.3}%
\contentsline {subsection}{\numberline {2.5.4}SNPs in ncRNA and their binding sites}{13}{subsection.2.5.4}%
\contentsline {subsection}{\numberline {2.5.5}Others}{13}{subsection.2.5.5}%
\contentsline {section}{\numberline {2.6}Interplay between germline and somatic variants}{13}{section.2.6}%
\contentsline {section}{\numberline {2.7}Computational methods for identifying variants}{14}{section.2.7}%
\contentsline {section}{\numberline {2.8}Experimental approaches for functional validation}{14}{section.2.8}%
\contentsline {chapter}{\numberline {3}Advances in understanding cancer genomics through second-generation sequencing}{16}{chapter.3}%
\contentsline {section}{\numberline {3.1}Abstract}{16}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Introduction}{16}{subsection.3.1.1}%
\contentsline {section}{\numberline {3.2}Cancer-specific consideration}{16}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Characteristics of cancer samples for genomic analysis}{17}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Structural variability of cancer genomes}{17}{subsection.3.2.2}%
\contentsline {section}{\numberline {3.3}Experimental approaches}{17}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Whole genome sequencing}{17}{subsection.3.3.1}%
\contentsline {subsection}{\numberline {3.3.2}Exome sequencing}{17}{subsection.3.3.2}%
\contentsline {subsection}{\numberline {3.3.3}Transcriptome sequencing}{18}{subsection.3.3.3}%
\contentsline {section}{\numberline {3.4}Detecting classes of genome alterations}{18}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{18}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Copy number}{18}{subsection.3.4.2}%
\contentsline {subsection}{\numberline {3.4.3}Chromosomal rearrangements}{18}{subsection.3.4.3}%
\contentsline {subsection}{\numberline {3.4.4}Microbe-discovery methods}{19}{subsection.3.4.4}%
\contentsline {section}{\numberline {3.5}Computational issues}{19}{section.3.5}%
\contentsline {subsection}{\numberline {3.5.1}Alignment and assembly}{19}{subsection.3.5.1}%
\contentsline {subsection}{\numberline {3.5.2}mutations detection}{19}{subsection.3.5.2}%
\contentsline {subsection}{\numberline {3.5.3}Validation of mutation and rearrangement calls}{19}{subsection.3.5.3}%
\contentsline {chapter}{\numberline {4}Integrative genomics viewer}{21}{chapter.4}%
\contentsline {section}{\numberline {4.1}Introduction}{21}{section.4.1}%
\contentsline {chapter}{\numberline {5}Tumour heterogeneity and resistance to cancer therapies}{22}{chapter.5}%
\contentsline {section}{\numberline {5.1}Abstract}{22}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Introduction}{22}{subsection.5.1.1}%
\contentsline {section}{\numberline {5.2}Causes of intratumoral heterogeneity}{22}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Genomic instability}{22}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}The clonal evolution and selection hypothesis}{23}{subsection.5.2.2}%
\contentsline {section}{\numberline {5.3}The spectrum of tumour heterogeneity}{23}{section.5.3}%
\contentsline {subsection}{\numberline {5.3.1}Spatial heterogeneity}{23}{subsection.5.3.1}%
\contentsline {subsubsection}{\numberline {5.3.1.1}Heterogeneity at a single disease site}{23}{subsubsection.5.3.1.1}%
\contentsline {subsubsection}{\numberline {5.3.1.2}Comparison of spatially distinct disease sites}{23}{subsubsection.5.3.1.2}%
\contentsline {subsection}{\numberline {5.3.2}Temporal heterogeneity}{24}{subsection.5.3.2}%
\contentsline {subsubsection}{\numberline {5.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{24}{subsubsection.5.3.2.1}%
\contentsline {subsubsection}{\numberline {5.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{24}{subsubsection.5.3.2.2}%
\contentsline {subsubsection}{\numberline {5.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{24}{subsubsection.5.3.2.3}%
\contentsline {section}{\numberline {5.4}Noninvasive monitoring of heterogeneity}{25}{section.5.4}%
\contentsline {subsection}{\numberline {5.4.1}Analysis of ctDNA}{25}{subsection.5.4.1}%
\contentsline {section}{\numberline {5.5}Overcoming heterogeneity}{25}{section.5.5}%
\contentsline {chapter}{\numberline {6}Unravelling the clonal hierarchy of somatic genomic aberration}{27}{chapter.6}%
